XenoPort Inc. (Nasdaq: XNPT) reported positive results from a Phase 2
clinical trial of its psoriasis treatment XP23829 but the stock price tumbled $1.89 to close at $4.84.
XenoPort reports positive trial data
September 15, 2015 at 18:42 PM EDT
